Jump to content

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study (Q46630310)

From Wikidata
scientific article published in August 2005
edit
Language Label Description Also known as
default for all languages
No label defined
    English
    Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study
    scientific article published in August 2005

      Statements

      Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study (English)

      Identifiers

       
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      edit